UNASSIGNED: 217 Background: @entity417 ( @entity417 ) is a frequent complication of @entity1 with @entity5 . The ORHEO (place of biOsimilaRs in the therapeutic management of @entity417 secondary to chemotherapy in HaEmatology and Oncology) study was a post-marketing, observational, multicentre study conducted in France that evaluated the changes in haemoglobin (Hb) level in @entity1 with solid @entity5 , @entity706 or @entity1582 , treated with an @entity1307 alfa biosimilar (EAB) (Retacrit, Hospira Inc.). In this subanalysis of the ORHEO study, we compare the usage of EAB in relation to the dosage recommendations of the European Organisation for Research and Treatment of @entity5 (EORTC) guidelines, regarding two criteria: efficacy and safety profile. METHODS: @entity1 with @entity417 receiving chemotherapy for solid @entity5 (breast, lung, colorectal), @entity706 or @entity1582 , and prescribed EAB were monitored at the start of the EAB therapy (D0), at 3 months (M3) and 6 months (M6). Hb response was defined as achievement of target Hb without blood transfusions in the preceding 3 weeks and during treatment or Hb >= 10 g/dL orHb increase >= 1 g/dL since inclusion. The prescribed dosage of EAB according to body weight and the tolerability of EAB at that recommended dosage were analysed at each time point. RESULTS: Data from 2310 @entity1 were analysed. Throughout the study 43.8% of @entity1 received the recommended dose of EAB as determined by their weight. Overall, the percentage of responders was 81.6% at M3 and 86.5% at M6. Responses to treatment (meeting predefined Hb target levels) at M6 were similar whether or not EAB was prescribed at the recommended dose throughout the study. A similar proportion of @entity1 receiving the recommended dose of EAB reported adverse events (AEs) at M6 compared with @entity1 who did not receive the recommended dose (9.9% vs 9.0%). Overall, the incidence of @entity1031 events was 3.5% over the duration of the study (M3 2.4%; M6 1.5%). CONCLUSIONS: Of the 2310 @entity1 with @entity417 included in this analysis, less than half (43.8%) received the recommended dose of EAB over the six-month course of the study. The majority of @entity1 had a similar response to therapy regardless of dose. The frequency of overall AEs at M6 did not vary depending on dose. CLINICAL TRIAL INFORMATION: NCT02140736.

Good usage of XXXX alpha biosimilar: A subanalysis of the orheo study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia', 'Chemotherapy-induced anaemia', 'CIA'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumours', 'Cancer'] @entity1307 :: ('2056', 'Gene') :: ['epoetin'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic']
@entity1307 :: (2056,Gene) :: ['epoetin']
